Form 10-KT - Transition reports [Rule 13a-10 or 15d-10]:
SEC Accession No. 0001013596-10-000032
Filing Date
2010-03-30
Accepted
2010-03-29 17:31:51
Documents
10
Period of Report
2009-12-31

Document Format Files

Seq Description Document Type Size
1 TRANSITION FORM 10-K FOR FISCAL YEAR ENDED DECEMBER 31, 2009 fm10k_12-09.htm 10-KT 646477
2 GRAPHIC img1.gif GRAPHIC 26837
3 GRAPHIC img2.gif GRAPHIC 49078
4 GRAPHIC img3.jpg GRAPHIC 9894
5 GRAPHIC img4.gif GRAPHIC 26837
6 GRAPHIC img5.gif GRAPHIC 49078
7 GRAPHIC img6.jpg GRAPHIC 9894
8 CERTIFICATION OF CHIEF EXECUTIVE OFFICER exh31-1.htm EX-31 14527
9 CERTIFICATION OF CHIEF FINANCIAL OFFICER exh31-2.htm EX-31 14098
10 CERTIFICATION OF CHIEF EXECUTIVE AND CHIEF FINANCIAL OFFICERS exh32.htm EX-32 5878
  Complete submission text file 0001013596-10-000032.txt   919854
Mailing Address 6100 ROYALMOUNT AVENUE MONTREAL A8 H4P 2R2
Business Address 6100 ROYALMOUNT AVENUE MONTREAL A8 H4P 2R2 514-496-5197
Sunshine Biopharma, Inc (Filer) CIK: 0001402328 (see all company filings)

EIN.: 205566275 | State of Incorp.: CO | Fiscal Year End: 1231
Type: 10-KT | Act: 34 | File No.: 000-52898 | Film No.: 10711599
SIC: 8742 Services-Management Consulting Services